DP
Insider
Decheng Capital Global Life Sciences Fund IV, L.P.
10% ownerDecheng Capital Global Life Sciences Fund IV, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in Aardvark Therapeutics, Inc. (AARD). Across 1 priced purchase filing, the average 21-session return was -35.4% from execution and -29.2% from disclosure (delay-adjusted; derived). The largest single filing was $20.0M of AARD (1,250,000 sh across 2 lots, as filed), executed Feb 14 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-35.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-29.2%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
5d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$20.0M
shares × price, as filed
Last traded
Feb 14 2025
Filed Feb 19 2025
Median ADV $1.3M across their filed names
Open performance→Volume by month
Buys $20.0M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 24 months
Most traded names
AARDRecent filings
AARDPURCHASE
Aardvark Therapeutics, Inc.
View filing →
$20.0M1,250,000 sh across 2 lots
Exec Feb 14 2025
Filed Feb 19 2025 · 5:30 PM ET